KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Non-Current Deffered Revenue (2016 - 2025)

Pacific Biosciences Of California (PACB) has 15 years of Non-Current Deffered Revenue data on record, last reported at $4.4 million in Q3 2025.

  • For Q3 2025, Non-Current Deffered Revenue changed N/A year-over-year to $4.4 million; the TTM value through Sep 2025 reached $4.4 million, changed N/A, while the annual FY2024 figure was $5.9 million, 6.69% up from the prior year.
  • Non-Current Deffered Revenue reached $4.4 million in Q3 2025 per PACB's latest filing, down from $5.7 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $25.2 million in Q1 2022 and bottomed at $1.8 million in Q3 2022.
  • Average Non-Current Deffered Revenue over 5 years is $9.3 million, with a median of $5.7 million recorded in 2021.
  • Peak YoY movement for Non-Current Deffered Revenue: soared 1497.51% in 2021, then crashed 92.84% in 2022.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $25.0 million in 2021, then plummeted by 92.84% to $1.8 million in 2022, then skyrocketed by 208.25% to $5.5 million in 2023, then grew by 6.69% to $5.9 million in 2024, then fell by 25.42% to $4.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $4.4 million in Q3 2025, $5.7 million in Q2 2025, and $5.9 million in Q4 2024.